Immune infiltration and prostate cancer

Frontiers in Oncology

Volumn 5, Issue MAY, 2015, Pages

  Strasner, Amy ^a   Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B cells; Immune cells; Immunotherapy; Inflammation; Prostate Cancer

Indexed keywords

AGLATIMAGENE BESADENOVEC; ENZALUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INDOXIMOD; IPILIMUMAB; LIRILUMAB; PIDILIZUMAB; RILIMOGENE GALVACIREPVEC; RITUXIMAB; SIPULEUCEL T;

ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL INFILTRATION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; VACCINATION;

EID: 84935066963     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00128     Document Type: Article

References (95)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, Cancer statistics, 2014. CA: a cancer journal for clinicians 64 (2014) 9-29.
2. M.A. Uhlman, Megan T. Bing, and David M. Lubaroff, Prostate cancer vaccines in combination with additional treatment modalities. Immunological Research 59 (2014) 236-242.
3. P.W. Kantoff, P.R. Carroll, and A.V. D'Amico, eds., Prostate cancer: principles and practice., Lippincott William & Wilkins, Philadelphia, 2002.
4. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I.F. Tannock, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26 (2008) 242-5.
5. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara, Jr., J.A. Jones, M.E. Taplin, P.A. Burch, D. Berry, C. Moinpour, M. Kohli, M.C. Benson, E.J. Small, D. Raghavan, and E.D. Crawford, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine 351 (2004) 1513-20.
6. I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi, S. Oudard, C. Theodore, N.D. James, I. Turesson, M.A. Rosenthal, and M.A. Eisenberger, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine 351 (2004) 1502-12.
7. E. Basch, K. Autio, C.J. Ryan, P. Mulders, N. Shore, T. Kheoh, K. Fizazi, C.J. Logothetis, D. Rathkopf, M.R. Smith, P.N. Mainwaring, Y. Hao, T. Griffin, S. Li, M.L. Meyers, A. Molina, and C. Cleeland, Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet. Oncology 14 (2013) 1193-9.
8. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman, Jr., F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, and H.I. Scher, Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine 364 (2011) 1995-2005.
9. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Flechon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, and J.S. de Bono, Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine 367 (2012) 1187-97.
10. A.J. Schrader, M. Boegemann, C.H. Ohlmann, T.J. Schnoeller, L.M. Krabbe, T. Hajili, F. Jentzmik, M. Stoeckle, M. Schrader, E. Herrmann, and M.V. Cronauer, Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. European urology 65 (2014) 30-6.
11. Z. Culig, Targeting the androgen receptor in prostate cancer. Expert Opin Pharmacother 15 (2014) 1427-1437.
12. G. Taverna, G. Giusti, M. Seveso, R. Hurle, P. Colombo, S. Stifter, and F. Grizzi, Mast cells as a potential prognostic marker in prostate cancer. Disease markers 35 (2013) 711-20.
13. J. Xu, J. Sun, and S.L. Zheng, Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian journal of andrology 15 (2013) 314-22.
14. M.J. Morris, K.A. Autio, E.M. Basch, D.C. Danila, S. Larson, and H.I. Scher, Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Seminars in oncology 40 (2013) 375-92.
15. C.J. Ryan, S. Shah, E. Efstathiou, M.R. Smith, M.E. Taplin, G.J. Bubley, C.J. Logothetis, T. Kheoh, C. Kilian, C.M. Haqq, A. Molina, and E.J. Small, Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clinical cancer research: an official journal of the American Association for Cancer Research 17 (2011) 4854-61.
16. V.A. Moyer, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 157 (2012) 120-34.
17. M.D. Hall, Timothy E. Schultheiss, Ginamarie Farino, and Jeffrey Y.C. Wong, Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF). Journal of clinical oncology: official journal of the American Society of Clinical Oncology 33 (2015) abstract 143.
18. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, Cancer-related inflammation. Nature 454 (2008) 436-44.
19. A. Kuraishy, M. Karin, and S.I. Grivennikov, Tumor promotion via injury- and death-induced inflammation. Immunity 35 (2011) 467-77.
20. A.C. Vidal, L.E. Howard, D.M. Moreira, R. Castro-Santamaria, G.L. Andriole, and S.J. Freedland, Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study. Clinical cancer research: an official journal of the American Association for Cancer Research 21 (2015) 756-62.
21. R. Bardan, R. Dumache, A. Dema, A. Cumpanas, and V. Bucuras, The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clinical biochemistry 47 (2014) 909-15.
22. A.M. De Marzo, E.A. Platz, S. Sutcliffe, J. Xu, H. Gronberg, C.G. Drake, Y. Nakai, W.B. Isaacs, and W.G. Nelson, Inflammation in prostate carcinogenesis. Nature reviews. Cancer 7 (2007) 256-69.
23. J.E. Elkahwaji, The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Research and reports in urology 5 (2012) 1-10.
24. Y.a.N.N. Nakai, Inflammation and prostate carcinogenesis. International Journal of Urology 20 (2013) 150-160.
25. K.S. Sfanos, and A.M. De Marzo, Prostate cancer and inflammation: the evidence. Histopathology 60 (2012) 199-215.
26. S. Vasto, G. Carruba, G. Candore, E. Italiano, D. Di Bona, and C. Caruso, Inflammation and prostate cancer. Future oncology (London, England) 4 (2008) 637-45.
27. A.W. Hsing, L. Tsao, and S.S. Devesa, International trends and patterns of prostate cancer incidence and mortality. International journal of cancer. Journal international du cancer 85 (2000) 60-7.
28. J. Peto, Cancer epidemiology in the last century and the next decade. Nature 411 (2001) 390-5.
29. S. Davidsson, M. Fiorentino, O. Andren, F. Fang, L.A. Mucci, E. Varenhorst, K. Fall, and J.R. Rider, Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20 (2011) 2280-7.
30. A. Vral, V. Magri, E. Montanari, G. Gazzano, V. Gourvas, E. Marras, and G. Perletti, Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients. International journal of oncology 41 (2012) 1950-8.
31. J. Jiang, J. Li, Z. Yunxia, H. Zhu, J. Liu, and C. Pumill, The role of prostatitis in prostate cancer: meta-analysis. PloS one 8 (2013) e85179.
32. L.K. Dennis, C.F. Lynch, and J.C. Torner, Epidemiologic association between prostatitis and prostate cancer. Urology 60 (2002) 78-83.
33. J. Irani, J.M. Goujon, E. Ragni, L. Peyrat, J. Hubert, F. Saint, and N. Mottet, High grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 54 (1999) 467-72.
34. G.T. MacLennan, R. Eisenberg, R.L. Fleshman, J.M. Taylor, P. Fu, M.I. Resnick, and S. Gupta, The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. The Journal of urology 176 (2006) 1012-6.
35. R.O. Roberts, E.J. Bergstralh, S.E. Bass, M.M. Lieber, and S.J. Jacobsen, Prostatitis as a risk factor for prostate cancer. Epidemiology (Cambridge, Mass.) 15 (2004) 93-9.
36. P.F. Engelhardt, H. Brustmann, S. Seklehner, and C.R. Riedl, Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: is there a correlation? Scandinavian journal of urology 47 (2013) 230-5.
37. B. Gurel, M.S. Lucia, I.M. Thompson, Jr., P.J. Goodman, C.M. Tangen, A.R. Kristal, H.L. Parnes, A. Hoque, S.M. Lippman, S. Sutcliffe, S.B. Peskoe, C.G. Drake, W.G. Nelson, A.M. De Marzo, and E.A. Platz, Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 23 (2014) 847-56.
38. D.M. Moreira, J.C. Nickel, L. Gerber, R.L. Muller, G.L. Andriole, R. Castro- Santamaria, and S.J. Freedland, Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 120 (2014) 190-6.
39. P. Pepe, and F. Aragona, Does an inflammatory pa ttern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urologia internationalis 87 (2011) 171-4.
40. T.H. Yli-Hemminki, M. Laurila, A. Auvinen, L. Maattanen, H. Huhtala, T.L. Tammela, and P.M. Kujala, Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU international 112 (2013) 735-41.
41. G. Li, H. Wang, A.B. Liu, C. Cheung, K.R. Reuhl, M.C. Bosland, and C.S. Yang, Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice. Cancer prevention research (Philadelphia, Pa.) 5 (2012) 963-72.
42. B.J. Boehm, S.A. Colopy, T.J. Jerde, C.J. Loftus, and W. Bushman, Acute bacterial inflammation of the mouse prostate. The Prostate 72 (2012) 307-17.
43. M. Khalili, L.N. Mutton, B. Gurel, J.L. Hicks, A.M. De Marzo, and C.J. Bieberich, Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. The American journal of pathology 176 (2010) 2259-68.
44. D.B. Shinohara, A.M. Vaghasia, S.H. Yu, T.N. Mak, H. Bruggemann, W.G. Nelson, A.M. De Marzo, S. Yegnasubramanian, and K.S. Sfanos, A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. The Prostate 73 (2013) 1007-15.
45. M. Ammirante, J.L. Luo, S. Grivennikov, S. Nedospasov, and M. Karin, B-cell derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464 (2010) 302-5.
46. M. Mercader, B.K. Bodner, M.T. Moser, P.S. Kwon, E.S. Park, R.G. Manecke, T.M. Ellis, E.M. Wojcik, D. Yang, R.C. Flanigan, W.B. Waters, W.M. Kast, and E.D. Kwon, T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 98 (2001) 14565-70.
47. O.J. Kwon, L. Zhang, M.M. Ittmann, and L. Xin, Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proceedings of the National Academy of Sciences of the United States of America 111 (2014) E592-600.
48. S.J. Ellem, H. Wang, M. Poutanen, and G.P. Risbridger, Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. The American journal of pathology 175 (2009) 1187-99.
49. A. Birbach, D. Eisenbarth, N. Kozakowski, E. Ladenhauf, M. Schmidt-Supprian, and J.A. Schmid, Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia (New York, N.Y.) 13 (2011) 692-703.
50. A. Flammiger, F. Bayer, A. Cirugeda-Kuhnert, H. Huland, P. Tennstedt, R. Simon, S. Minner, C. Bokemeyer, G. Sauter, T. Schlomm, and M. Trepel, Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS: acta pathologica, microbiologica, e t immunologica Scandinavica 120 (2012) 901-8.
51. P.A. Savage, K. Vosseller, C. Kang, K. Larimore, E. Riedel, K. Wojnoonski, A.A. Jungbluth, and J.P. Allison, Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (New York, N.Y.) 319 (2008) 215-20.
52. K. Ebelt, G. Babaryka, B. Frankenberger, C.G. Stief, W. Eisenmenger, T. Kirchner, D.J. Schendel, and E. Noessner, Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. European journal of cancer (Oxford, England: 1990) 45 (2009) 1664-72.
53. K.S. Sfanos, T.C. Bruno, A.K. Meeker, A.M. De Marzo, W.B. Isaacs, and C.G. Drake, Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD- 1+. The Prostate 69 (2009) 1694-703.
54. M. Lanciotti, L. Masieri, M.R. Raspollini, A. Minervini, A. Mari, G. Comito, E. Giannoni, M. Carini, P. Chiarugi, and S. Serni, The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. BioMed research international 2014 (2014) 486798.
55. P.O. Gannon, A.O. Poisson, N. Delvoye, R. Lapointe, A.M. Mes-Masson, and F. Saad, Characterization of the intra-prostatic immune cell infiltration in androgen deprived prostate cancer patients. Journal of immunological methods 348 (2009) 9-17.
56. N. Nonomura, H. Takayama, M. Nakayama, Y. Nakai, A. Kawashima, M. Mukai, A. Nagahara, K. Aozasa, and A. Tsujimura, Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU international 107 (2011) 1918-22.
57. J. Escamilla, S. Schokrpur, C. Liu, S.J. Priceman, D. Moughon, Z. Jiang, F. Pouliot, C. Magyar, J.L. Sung, J. Xu, G. Deng, B.L. West, G. Bollag, Y. Fradet, L. Lacombe, M.E. Jung, J. Huang, and L. Wu, CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. Cancer research 75 (2015) 950-62.
58. A. Valdman, S.J. Jaraj, E. Comperat, F. Charlotte, M. Roupret, P. Pisa, and L. Egevad, Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 118 (2010) 360-5.
59. D. Di Mitri, A. Toso, J.J. Chen, M. Sarti, S. Pinton, T.R. Jost, R. D'Antuono, E. Montani, R. Garcia-Escudero, I. Guccini, S. Da Silva-Alvarez, M. Collado, M. Eisenberger, Z. Zheng, C. Catapano, F. Grassi, and A. Alimonti, Tumour infiltrating Gr-1 myeloid cells antagonize senescence in cancer. Nature (2014).
60. A.J. Garcia, M. Ruscetti, T.L. Arenzana, L.M. Tran, D. Bianci-Frias, E. Sybert, S.J. Priceman, L. Wu, P.S. Nelson, S.T. Smale, and H. Wu, Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Molecular and cellular biology 34 (2014) 2017-28.
61. M. Idorn, T. Kollgaard, P. Kongsted, L. Sengelov, and P. Thor Straten, Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration resistant metastatic prostate cancer. Cancer immunology, immunotherapy: CII (2014).
62. E. Derhovanessian, V. Adams, K. Hahnel, A. Groeger, H. Pandha, S. Ward, and G. Pawelec, Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. International journal of cancer. Journal international du cancer 125 (2009) 1372-9.
63. A. Johansson, S. Rudolfsson, P. Hammarsten, S. Halin, K. Pietras, J. Jones, P. Stattin, L. Egevad, T. Granfors, P. Wikstrom, and A. Bergh, Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. The American journal of pathology 177 (2010) 1031-41.
64. P. Pittoni, C. Tripodo, S. Piconese, G. Mauri, M. Parenza, A. Rigoni, S. Sangaletti, and M.P. Colombo, Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer research 71 (2011) 5987-97.
65. S. Tang, M.L. Moore, J.M. Grayson, and P. Dubey, Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer research 72 (2012) 1975-85.
66. M. Ammirante, S. Shalapour, Y. Kang, C.A. Jamieson, and M. Karin, Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America 111 (2014) 14776-81.
67. K.R. Reddy, Y. Guan, G. Qin, Z. Zhou, and N. Jing, Combined treatment targeting HIF-1alpha and Stat3 is a potent strategy for prostate cancer therapy. The Prostate 71 (2011) 1796-809.
68. M. Ammirante, A.I. Kuraishy, S. Shalapour, A. Strasner, C. Ramirez-Sanchez, W. Zhang, A. Shabaik, and M. Karin, An IKKalpha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes & development 27 (2013) 1435-40.
69. S. Shalapour, J. Font-Burgada, G. Di Caro, Z. Zhong, K. Wang, M. Ammirante, E. Sanchez-Lopez, G. Willimsky, A. Strasner, P. Bimer, L. Kenner, and M. Karin., Immunosuppressive plasma cells impede T cell-dependent immunogenic chemotherapy. Nature (2015) In press.
70. J.R. Woo, M.A. Liss, M.T. Muldong, K. Palazzi, A. Strasner, M. Ammirante, N. Varki, A. Shabaik, S. Howell, C.J. Kane, M. Karin, and C.A. Jamieson, Tumor infiltrating B-cells are increased in prostate cancer tissue. Journal of translational medicine 12 (2014) 30.
71. A. Dalgleish, P. Featherstone, V. Vlassov, and M. Rogosnitzky, Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature. Investigational new drugs 32 (2014) 1048-52.
72. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, D.F. Penson, C.H. Redfern, A.C. Ferrari, R. Dreicer, R.B. Sims, Y. Xu, M.W. Frohlich, and P.F. Schellhammer, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine 363 (2010) 411-22.
73. W.R. Gerritsen, The evolving role of immunotherapy i n prostate cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 23 Suppl 8 (2012) viii22-7.
74. N. Rigamonti, and M. Bellone, Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer immunology, immunotherapy: CII 61 (2012) 453-68.
75. J.W. Simons, B. Mikhak, J.F. Chang, A.M. DeMarzo, M.A. Carducci, M. Lim, C.E. Weber, A.A. Baccala, M.A. Goemann, S.M. Clift, D.G. Ando, H.I. Levitsky, L.K. Cohen, M.G. Sanda, R.C. Mulligan, A.W. Partin, H.B. Carter, S. Piantadosi, F.F. Marshall, and W.G. Nelson, Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer research 59 (1999) 5160-8.
76. J.W. Simons, and N. Sacks, Granulocyte-macrophage colony-stimulating factor transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urologic oncology 24 (2006) 419-24.
77. E.J. Small, P. Fratesi, D.M. Reese, G. Strang, R. Laus, M.V. Peshwa, and F.H. Valone, Immunotherapy of hormone-refractory prostate cancer with antigen loaded dendritic cells. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 18 (2000) 3894-903.
78. C. Jochems, J.A. Tucker, K.Y. Tsang, R.A. Madan, W.L. Dahut, D.J. Liewehr, S.M. Steinberg, J.L. Gulley, and J. Schlom, A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer immunology, immunotherapy: CII 63 (2014) 407-18.
79. E.N. Klyushnenkova, V.B. Riabov, D.V. Kouiavskaia, A. Wietsma, M. Zhan, and R.B. Alexander, Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. The Prostate 74 (2014) 1423-32.
80. T. Fujii, K. Shimada, O. Asai, N. Tanaka, K. Fujimoto, K. Hirao, and N. Konishi, Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology: journal of immunopathology, molecular and cellular biology 80 (2013) 119-26.
81. H. Yuan, Y.H. Hsiao, Y. Zhang, J. Wang, C. Yin, R. Shen, and Y. Su, Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC cancer 13 (2013) 258.
82. K.S. Sfanos, T.C. Bruno, C.H. Maris, L. Xu, C.J. Thoburn, A.M. DeMarzo, A.K. Meeker, W.B. Isaacs, and C.G. Drake, Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clinical cancer research: an official journal of the American Association for Cancer Research 14 (2008) 3254-61.
83. K. Gollapudi, C. Galet, T. Grogan, H. Zhang, J.W. Said, J. Huang, D. Elashoff, S.J. Freedland, M. Rettig, and W.J. Aronson, Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. American journal of cancer research 3 (2013) 523-9.
84. M. Craig, C. Ying, and R.D. Loberg, Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. Journal of cellular biochemistry 103 (2008) 1-8.
85. A. Fleischmann, T. Schlomm, J. Kollermann, N. Sekulic, H. Huland, M. Mirlacher, G. Sauter, R. Simon, and A. Erbersdobler, Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. The Prostate 69 (2009) 976-81.
86. G. Sonpavde, G.R. Pond, A.J. Armstrong, S.J. Clarke, J.L. Vardy, A.J. Templeton, S.L. Wang, J. Paolini, I. Chen, E. Chow-Maneval, M. Lechuga, M.R. Smith, and M.D. Michaelson, Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer 12 (2014) 317-24.
87. K. Fujita, R. Imamura, G. Tanigawa, M. Nakagawa, T. Hayashi, N. Kishimoto, M. Hosomi, and S. Yamaguchi, Low serum neutrophil count predicts a positive prostate biopsy. Prostate cancer and prostatic diseases 15 (2012) 386-90.
88. A.T. Sumbul, A. Sezer, H. Abali, F. Kose, I. Gultepe, H. Mertsoylu, S. Muallaoglu, and O. Ozyilkan, Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. International urology and nephrology 46 (2014) 1531-5.
89. A.J. Templeton, C. Pezaro, A. Omlin, M.G. McNamara, R. Leibowitz-Amit, F.E. Vera-Badillo, G. Attard, J.S. de Bono, I.F. Tannock, and E. Amir, Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014).
90. P. Nuhn, A.M. Vaghasia, J. Goyal, X.C. Zhou, M.A. Carducci, M.A. Eisenberger, and E.S. Antonarakis, Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU international (2013).
91. K. Shafique, M.J. Proctor, D.C. McMillan, K. Qureshi, H. Leung, and D.S. Morrison, Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate cancer and prostatic diseases 15 (2012) 195-201.
92. N. Sadeghi, G.M. Badalato, G. Hruby, V. Grann, and J.M. McKiernan, Does absolute neutrophil count predict high tumor grade in African-American men with prostate cancer? The Prostate 72 (2012) 386-91.
93. R.S. DiPaola, M. Plante, H. Kaufman, D.P. Petrylak, R. Israeli, E. Lattime, K. Manson, and T. Schuetz, A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. Journal of translational medicine 4 (2006) 1.
94. M. Burotto, N. Singh, C.R. Heery, J.L. Gulley, and R.A. Madan, Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Frontiers in oncology 4 (2014) 351.
95. E.D. Kwon, C.G. Drake, H.I. Scher, K. Fizazi, A. Bossi, A.J. van den Eertwegh, M. Krainer, N. Houede, R. Santos, H. Mahammedi, S. Ng, M. Maio, F.A. Franke, S. Sundar, N. Agarwal, A.M. Bergman, T.E. Ciuleanu, E. Korbenfeld, L. Sengelov, S. Hansen, C. Logothetis, T.M. Beer, M.B. McHenry, P. Gagnier, D. Liu, and W.R. Gerritsen, Ipilimumab versus placebo a fter radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology 15 (2014) 700-12.